Dana-Farber Research News 12.15.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from November 16 - 30.

By
December 15, 2025
19 min

Dana-Farber

Overview

This report summarizes key research findings from Dana-Farber faculty, highlighting significant advancements in understanding and managing hematologic disorders and cancer. Notable studies include insights into hemophagocytic lymphohistiocytosis in adults and the role of PTEN loss in tumorigenesis.

Background

Hematologic disorders like hemophagocytic lymphohistiocytosis (HLH) pose significant risks due to unchecked immune activation and hyperinflammation, leading to high mortality rates if untreated. Understanding the mechanisms and management of HLH, particularly in adults, is crucial for improving patient outcomes. Additionally, the loss of tumor suppressor PTEN is linked to cancer progression, emphasizing the need for targeted therapies in PTEN-deficient tumors.

Data Highlights

No numerical data available in the provided source material.

Key Findings

HLH is a life-threatening condition characterized by systemic inflammation and multiorgan failure.
Primary HLH typically presents in childhood, while secondary HLH is more common in adults and can be triggered by various factors.
PTEN loss leads to enhanced phosphorylation of PI3K?, promoting tumorigenesis through complex interactions with EPHA2 and SRC.
Dasatinib effectively inhibits tumor progression in PTEN-null models, highlighting a potential therapeutic avenue.
BAX, a pro-apoptotic protein, can be inhibited by the dimerization of BCL-w, affecting apoptosis induction.

Clinical Implications

Early recognition and intervention in HLH are critical to prevent irreversible organ damage. The identification of p-PI3K?Y962 as a druggable target offers new avenues for treating PTEN-deficient cancers, potentially improving therapeutic outcomes.

Conclusion

The findings from Dana-Farber's recent research underscore the importance of understanding the pathophysiology of hematologic disorders and cancer to inform clinical practice and enhance patient care.